UPDATE -- Trado GmbH Announces That Berlin Court Intervenes and Grants Preliminary Injunction Against Matthias Woestmann and Associates, Who Lost Millions of Envion Investor Money
Trado GmbH / UPDATE -- Trado GmbH Announces That Berlin Court Intervenes and Grants Preliminary Injunction Against Matthias Woestmann and Associates, Who Lost Millions of Envion Investor Money . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Victory for Envion Founders, As Quadrat Capital and Sycamore GmbH, Controlled by Woestmann, Thomas van Aubel, and Jutta Freifrau von Falkenhausen, Receive Setback
BERLIN, June 07, 2018 (GLOBE NEWSWIRE) -- The following are statements issued by Trado GmbH: Matthias Woestmann and his business associates, through their investment vehicles Quadrat Capital and Sycamore GmbH, received a striking blow on Tuesday from a Berlin judge in a ruling that may be the first of many setbacks for the current majority owners of Swiss blockchain infrastructure company envion AG. A preliminary injunction filed on behalf of envion's founders - led by Michael Luckow through the founders' company Trado GmbH - who claim rightful ownership of envion, was granted on Tuesday, June 5th, 2018.
Actions taken by Woestmann and the others follow a pattern used with previous companies involved in scandals across Germany. Evidence seen by the Berlin court was sufficient for the judge to rule that envion shares cannot be sold or traded to any 3rd party. The ruling further forbids envion's unlawful shareholders from transferring or debiting any of envion's assets. Envion's founders have stated that they will continue to file lawsuits in both German and Swiss courts until their majority is restored. The next court date is scheduled for June 21st.
The owners of the two holding companies (Quadrat Capital GmbH and Sycamore GmbH), Matthias Woestmann, Thomas van Aubel, Jutta Freifrau von Falkenhausen, and Dinnies von der Osten, have a history of profiting from investments in companies that fail spectacularly and under suspicious circumstances. They and their associates are linked to a long list of companies involved in some of Germany's largest financial scandals, including IGB, Balda (renamed to Clere), Q-cells, and Solon.
Mistakes made while executing the takeover of envion, which raised $100 million in an ICO in January, may keep envion from being their latest victim. Instead of a legal corporate takeover, Woestmann violated a contract which explicitly forbade him from actions compromising the majority ownership of the founders. Woestmann's inaction since the takeover has resulted in millions of dollars in lost dividends for investors and the founders being blocked from operating the company.
"Woestmann's serious missteps now threaten to bring his and his confederates' house of cards crashing down because he illegally created extra shares via an unauthorized capital increase which he then gave to Sycamore," said Michael Luckow, one of the founders of envion who have taken legal action against Woestmann and his associates.
Speaking to Swiss news service SWI, Woestmann did not deny charges that his actions were illegal when he diluted the founders' shares. Envion investors reported that he admitted his guilt in a call on May 28th which was widely discussed within the envion investor community, stating that he expected that he would be found guilty and would be liable for damages.
When solicitations distributed by Woestmann for bids to buy envion were attained by the founders, they moved quickly to file the court injunction. Documents show Woestmann attempting to sell envion for use as a "holding structure for new businesses to separate envion (sic) balance sheet from profitable businesses" and advertising that the "existing investor base can be used for all kinds of [other] business models" apart from the business that investors supported with $100 million.
About Trado GmbH
Trado GmbH holds the founders' shares in envion AG, a German-Swiss company that has developed a disruptive datacenter concept for crypto mining: a system of container-based mobile units that can be deployed right at the source of energy, either at the solar photovoltaic (PV) park or the power plant, providing the required flexibility for today's energy markets. Information about Trado and envion's founders can be found at www.envion-founders.org.
Chris Pfaff Tech Media LLC
NAÏMA Strategic Legal Services GmbH
phone: +49 30 2404 8290
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Trado GmbH via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Primal Pictures Partners with Physitrack to Create a Unique Patient Education Solution25.6.2018 18:00 | Pressemelding
LONDON, June 25, 2018 (GLOBE NEWSWIRE) -- Today, Primal Pictures, pioneer of the world's most medically-accurate and detailed 3D models of human anatomy, and Physitrack, the market-leading patient engagement and Telehealth solution provider, announce their partnership on a unique anatomically augmented home exercise and patient education feature. The feature inside Physitrack, which is powered by Primal Pictures, will allow healthcare practitioners to better educate their patients, and therefore help patients to improve their health outcomes. "Even the best physical therapy regime will be unsuccessful without proper patient education," explained Henrik Molin, CEO and co-founder of Physitrack. "That's why Physitrack developed what has become the industry's gold standard in patient engagement and outcome tracking. With Primal Pictures, we saw the opportunity to take our solution to a new level by helping patients make the connection between their physical therapy regime and the anatomy i
EPAM's InfoNgen(TM) Debuts With Highest Score Possible in Seven Criteria in AI-Based Text Analytics Platforms Report by Independent Research Firm25.6.2018 16:58 | Pressemelding
InfoNgen, categorized as one of the top eight providers that matter most, is a fully integrated, end-to-end turnkey solution that helps enterprises become more insights-driven NEWTOWN, Pa., June 25, 2018 (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, today announced that it has been named a Contender in the report "The Forrester Wave(TM): AI-Based Text Analytics Platforms, Q2 2018" for its product InfoNgen(TM). InfoNgen ranked among the highest scores in the enterprise features, RPA functionality, training data for machine learning, focus on cloud and SaaS, and overall revenue criteria. According to the report, "[EPAM's] InfoNgen text analytics product is a good example of how modern consulting firms and systems integrators differentiate - they productize solutions." "EPAM's inclusion in this report, along with leaders like IBM and SAS, demonstrates, in our opinion, our ability to extend e
Align Technology Reaches One Millionth Invisalign(R) Patient in the EMEA Region25.6.2018 16:00 | Pressemelding
Milestone Reflects Accelerating Adoption of Invisalign Treatment Among Adults and Teens in Europe SAN JOSE, Calif. and AMSTERDAM, The Netherlands, June 25, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq:ALGN), today announced that it shipped its one millionth Invisalign case for the EMEA region in April, 2018. This significant milestone for the company and the more than 34 thousand Invisalign-trained orthodontists and general dentists in the region reflects accelerating adoption of Invisalign clear aligner therapy in Europe, Middle East and Africa. "I am immensely proud to announce that we have reached yet another significant milestone for EMEA with our one millionth Invisalign patient in the region. The demand and adoption rate for Invisalign clear aligners in EMEA has accelerated rapidly during recent years. I would like to thank our doctors for their trust and confidence in treating patients with the Invisalign system, and acknowledge the more than one million patients in E
Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions25.6.2018 14:00 | Pressemelding
Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic disorder (HMD) by year-end VANCOUVER, British Columbia, June 25, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today announced that clinical data from a metreleptin study assessing weight loss in overweight and obese adults with low leptin levels will be featured in a poster presentation at the American Diabetes Association's (ADA) 78th Scientific Sessions, being held June 22-26, 2018 in Orlando. The study, titled "Efficacy of Metreleptin for Weight Loss in Overweight and Obese Adults With Low Leptin Levels," was conducted in adults with low baseline leptin, defined as <16 ng/mL in females and <5 ng/mL in males, and Body Mass Index (BMI) lev
ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia25.6.2018 00:06 | Pressemelding
Conference call on Monday, June 25th at 2:30 pm CET/8:30 am EDT Focuses development efforts on solid tumor indications Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer. Expands eryaspase production capacity in the United States and France Plans to cease development in acute lymphoblastic leukemia (ALL), including withdrawal of European Marketing Authorization Application (MAA) LYON, France and CAMBRIDGE Mass., June 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications. The company also announced that it plans to cease its development pro
CORRECTING and REPLACING -- PRESS ALERT & INVITATION: Arbitrade to Hold a Press Conference on June 28th From Bermuda - Its New Global Headquarters23.6.2018 14:00 | Pressemelding
NEW YORK, June 23, 2018 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by Arbitrade, please note that the correct date of the event is Thursday, June 28, 2018 at 8:00 a.m. EDT. The corrected release follows: This is an invitation to all media following Arbitrade and/or covering the cryptocurrency markets. You are invited to join Arbitrade's Chairman, Len Schutzman, and management who will discuss their progress toward establishing Arbitrade as a world-class cryptocurrency exchange and coin company. They will also discuss their move and incorporation into Bermuda, one of the world's best regulated jurisdictions and a platform from which Arbitrade will reach out to several international markets. It will be a lively discussion that will also include details of the many economic and social advantages and new jobs that companies, like Arbitrade, will bring to countries in which they settle and do business around the world. Details of how to access the pr
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom